Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Simulations Plus provides pharmaceutical modeling and simulation software used in drug discovery and development, primarily serving biopharma companies and regulatory agencies. The company's core products include GastroPlus for ADME modeling, DDDPlus for dissolution simulation, and consulting services that help clients optimize clinical trial design and regulatory submissions. Recent severe margin compression (-89% operating margin) and -750% net income decline suggest significant operational challenges or one-time charges despite 13% revenue growth.
Simulations Plus monetizes proprietary simulation algorithms through software licenses sold to pharmaceutical and biotech companies for drug development. The business model combines high-margin recurring software revenue (maintenance contracts, subscriptions) with project-based consulting that leverages the same scientific expertise. Pricing power stems from regulatory acceptance of their models by FDA and EMA, creating switching costs once integrated into clients' workflows. The 58% gross margin reflects software economics, but the -89% operating margin indicates either aggressive R&D investment, acquisition integration costs, or restructuring charges that have temporarily destroyed profitability.
New pharmaceutical R&D spending trends and biotech funding environment (drives software license demand)
Large enterprise contract wins or renewals with top-20 pharma companies
Regulatory adoption of in-silico modeling (FDA guidance expanding use cases for simulation tools)
Acquisition integration success and return to positive operating margins
Quarterly software license bookings and consulting backlog trends
AI/machine learning disruption from tech giants (Google DeepMind, Nvidia) entering drug discovery with competing computational platforms
Regulatory risk if FDA/EMA reduce acceptance of in-silico modeling or require more extensive clinical validation
Consolidation in pharmaceutical industry reducing total number of potential enterprise clients
Competition from larger enterprise software vendors (Dassault Systèmes BIOVIA, Schrödinger) with broader product suites and sales resources
Open-source modeling tools and academic software reducing willingness to pay for proprietary solutions
In-house modeling capabilities development by large pharma companies reducing outsourcing demand
Severe profitability deterioration (-89% operating margin) creating cash burn risk if not reversed quickly
While current ratio of 5.62 suggests adequate liquidity, sustained losses could deplete cash reserves
Potential goodwill impairment risk if recent acquisitions underperform (common cause of margin compression)
moderate - Pharmaceutical R&D spending is relatively recession-resistant as drug development timelines span years and regulatory requirements don't change with economic cycles. However, biotech funding (venture capital, IPOs) is highly cyclical and affects smaller clients' ability to purchase software. Large pharma clients provide stability, but emerging biotech represents growth opportunity that contracts during downturns.
Rising interest rates negatively impact the biotech funding environment, reducing venture capital availability and IPO activity for smaller pharmaceutical companies that represent growth customers. Higher rates also pressure valuation multiples for unprofitable software companies. The company's zero debt means no direct financing cost impact, but customer financing conditions matter significantly.
Moderate exposure through biotech customer base. Tighter credit conditions reduce venture funding for early-stage drug developers, potentially leading to customer churn or delayed purchases. Large pharmaceutical clients have minimal credit risk, but smaller biotech customers may face liquidity challenges in restrictive credit environments.
growth - Small-cap healthcare technology play historically attracted growth investors betting on pharmaceutical digitalization trends and recurring software revenue models. However, the -66% one-year return and profitability collapse have likely shifted the shareholder base toward distressed/turnaround investors or those betting on operational restructuring. High volatility and small market cap ($200M) limit institutional ownership.
high - Small-cap software stock with limited float, binary dependence on enterprise contract wins, and recent severe financial deterioration create high volatility. The -26% three-month return demonstrates downside volatility, typical for micro-cap healthcare IT stocks with execution risk.
